Beam Therapeutics Inc. (NASDAQ: BEAM) is a top biotech stock with high potential. Analysts like H.C. Wainwright and Kostas Biliouris maintain Buy ratings on BEAM, with price targets of $80 and $40, respectively, citing strong momentum and technological advancements. Beam focuses on precision genetic medicines through base editing technology for various genetic diseases. While BEAM shows promise, some believe AI stocks offer greater upside potential.

Read more at Yahoo Finance: What Does Wall Street Think About Beam Therapeutics (BEAM)?